Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 302

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 1C
Chunk 302
---
 HSV1 viral therapeutic platform
to engineer immunotherapies for a variety of diseases. We have signed exclusive worldwide License Agreements with JHU for a cancer drug
that targets glioblastoma (brain cancer), pancreatic cancer, and others. We have also signed an exclusive worldwide license from George
Washington University for another cancer drug that targets hepatocellular carcinoma (liver cancer) and other liver diseases. In addition,
we have signed three-year strategic data and commercialization agreements with the Lieber Institute for Brain Development (“LIBD”)
whom we believe has a repository of the largest collection of postmortem brains in the world, including molecular, clinical, and other
data. The objective of this collaboration with LIBD is for the Company to analyze these rich data sets using its proprietary AI/ML tools
and models and then go to market with the discoveries with the ultimate goal of securing revenue generating strategic partnership deals
with biopharmaceutical companies. We intend to secure the rights to other proprietary data sets and repeat this strategy. Additionally,
we intend to gain access to later-stage clinical assets through partnerships or the acquisition of rights to failed therapeutic candidates
for drug rescue. In certain circumstances, we intend to conduct late-stage clinical trials in an effort to rescue therapeutic assets
that previously failed. In these cases, there will be a requirement for drug supply and regulatory services to conduct clinical trials.
The success of our clinical development programs will require finding partners to support the clinical development, adequate availability
of raw materials and/or drug product for our R&D and clinical trials, and, in some cases, may also require establishment of third-party
arrangements to obtain finished drug product that is manufactured appropriately under good manufacturing practices, and packaged for
clinical use or sale. Since we are a company focused on using our AI/ML technology to advance medicines, any clinical development programs
will also require, in all cases, partners and the establishment of third-party relationships for execution and completion of clinical
trials.

 25 

Since
completing our initial public offering in February 2023 (the “IPO”), aided by the receipt of the IPO proceeds in addition
to the proceeds from our February 2024 and October 2024 offerings, we have implemented several initiatives: investor relations and marketing
to promote and raise awareness of the Company in the financial and business sectors, research and development, collaboration with J Craig
Venter Institute (“JCVI”) and initiated preclinical studies with our in-licensed drug programs